ArticleJournal of pharmaceutical analysis2026
Flavonoid compounds from Shenrong Guben Huanshao Pill alleviates senescence-associated mitochondrial dysfunction through NDUFV2 and LDHB mediated metabolic reprogramming.
Article in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Senescence is widely recognized as a key driving factor in the onset and progression of many chronic diseases. Although numerous animal studies have demonstrated that various drugs can delay senescence, their clinical application is severely limited due to significant toxic side effects. As a result, developing safer, natural anti-senescence agents has become an urgent priority. In this study, we identified mitochondrial dysfunction as a critical contributor to cellular senescence. In addition, we identified Shenrong Guben Huanshao Pill (SRW) as an effective agent that alleviates mitochondrial dysfunction and consequently delays cellular senescence by regulating mitochondrial metabolism. Mechanistically, SRW enhances mitochondrial function by upregulating the expression of reduced nicotinamide adenine dinucleotide (NADH):ubiquinone oxidoreductase subunit V2 (NDUFV2), a core component of mitochondrial respiratory chain complex I. Simultaneously, SRW reduces lactate-induced mitochondrial dysfunction by regulating the glycolytic enzyme lactate dehydrogenase B (LDHB), thereby decreasing lactate accumulation. Collectively, our findings indicate that SRW alleviates cellular senescence by coordinately regulating NDUFV2 expression and LDHB-mediated lactate metabolism to improve mitochondrial function. In addition, several flavonoids in SRW were identified to possess potential anti-senescence activity. Molecular docking and cellular experiments confirmed that myricetin, luteolin, and gamma-mangostin effectively alleviate cellular senescence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.